JP7254835B2 - 配合剤送達装置 - Google Patents
配合剤送達装置 Download PDFInfo
- Publication number
- JP7254835B2 JP7254835B2 JP2020563421A JP2020563421A JP7254835B2 JP 7254835 B2 JP7254835 B2 JP 7254835B2 JP 2020563421 A JP2020563421 A JP 2020563421A JP 2020563421 A JP2020563421 A JP 2020563421A JP 7254835 B2 JP7254835 B2 JP 7254835B2
- Authority
- JP
- Japan
- Prior art keywords
- delivery device
- drug
- spike plate
- module
- hole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000012377 drug delivery Methods 0.000 title claims description 24
- 229940000425 combination drug Drugs 0.000 title claims 3
- 239000003814 drug Substances 0.000 claims description 92
- 229940079593 drug Drugs 0.000 claims description 85
- 239000012530 fluid Substances 0.000 claims description 17
- 238000009472 formulation Methods 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 239000005557 antagonist Substances 0.000 description 53
- 239000012634 fragment Substances 0.000 description 30
- 239000000556 agonist Substances 0.000 description 27
- 239000000427 antigen Substances 0.000 description 27
- 102000036639 antigens Human genes 0.000 description 27
- 108091007433 antigens Proteins 0.000 description 27
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 24
- 210000001744 T-lymphocyte Anatomy 0.000 description 24
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 24
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 22
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 22
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 21
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 21
- 239000007788 liquid Substances 0.000 description 17
- 239000003112 inhibitor Substances 0.000 description 13
- 229960003301 nivolumab Drugs 0.000 description 13
- 230000037361 pathway Effects 0.000 description 13
- 229920001184 polypeptide Polymers 0.000 description 13
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 229940045513 CTLA4 antagonist Drugs 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 108010029697 CD40 Ligand Proteins 0.000 description 11
- 102100032937 CD40 ligand Human genes 0.000 description 11
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 11
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 11
- 239000003623 enhancer Substances 0.000 description 11
- 238000001802 infusion Methods 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 9
- 238000003780 insertion Methods 0.000 description 9
- 230000037431 insertion Effects 0.000 description 9
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 8
- 102000017578 LAG3 Human genes 0.000 description 8
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 8
- 229960002621 pembrolizumab Drugs 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000013329 compounding Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 101000597780 Mus musculus Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 description 6
- 101710136122 Tryptophan 2,3-dioxygenase Proteins 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 229940124981 favezelimab Drugs 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 102100024263 CD160 antigen Human genes 0.000 description 5
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 5
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 5
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 description 5
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 description 5
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 5
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 description 5
- 102100040653 Tryptophan 2,3-dioxygenase Human genes 0.000 description 5
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 5
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 5
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 5
- 229940029030 dendritic cell vaccine Drugs 0.000 description 5
- 238000003881 globally optimized alternating phase rectangular pulse Methods 0.000 description 5
- 229960005386 ipilimumab Drugs 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 229940055760 yervoy Drugs 0.000 description 5
- 101150051188 Adora2a gene Proteins 0.000 description 4
- 229940123205 CD28 agonist Drugs 0.000 description 4
- 229940123189 CD40 agonist Drugs 0.000 description 4
- 229940121850 CD86 agonist Drugs 0.000 description 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 4
- 102000002698 KIR Receptors Human genes 0.000 description 4
- 108010043610 KIR Receptors Proteins 0.000 description 4
- YGACXVRLDHEXKY-WXRXAMBDSA-N O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 Chemical compound O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 YGACXVRLDHEXKY-WXRXAMBDSA-N 0.000 description 4
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
- 230000000735 allogeneic effect Effects 0.000 description 4
- 229940121413 bempegaldesleukin Drugs 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 229940121697 CD27 agonist Drugs 0.000 description 3
- 229940122551 CD40 antagonist Drugs 0.000 description 3
- 102100025221 CD70 antigen Human genes 0.000 description 3
- 101710093674 Cyclic nucleotide-gated cation channel beta-1 Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 3
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 3
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 3
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 3
- 102100034980 ICOS ligand Human genes 0.000 description 3
- 101710093458 ICOS ligand Proteins 0.000 description 3
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 3
- 102100025946 Transforming growth factor beta activator LRRC32 Human genes 0.000 description 3
- 101710169732 Transforming growth factor beta activator LRRC32 Proteins 0.000 description 3
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 3
- 230000002494 anti-cea effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- 229940126534 drug product Drugs 0.000 description 3
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 229950004563 lucatumumab Drugs 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- ZADWXFSZEAPBJS-SNVBAGLBSA-N (2r)-2-amino-3-(1-methylindol-3-yl)propanoic acid Chemical group C1=CC=C2N(C)C=C(C[C@@H](N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-SNVBAGLBSA-N 0.000 description 2
- YPBKTZBXSBLTDK-PKNBQFBNSA-N (3e)-3-[(3-bromo-4-fluoroanilino)-nitrosomethylidene]-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole Chemical compound NS(=O)(=O)NCCNC1=NON\C1=C(N=O)/NC1=CC=C(F)C(Br)=C1 YPBKTZBXSBLTDK-PKNBQFBNSA-N 0.000 description 2
- UJZDIKVQFMCLBE-UHFFFAOYSA-N 1-(4-ethylphenyl)-3-(1h-indol-3-yl)urea Chemical group C1=CC(CC)=CC=C1NC(=O)NC1=CNC2=CC=CC=C12 UJZDIKVQFMCLBE-UHFFFAOYSA-N 0.000 description 2
- HQSBCDPYXDGTCL-UHFFFAOYSA-N 3-[(4-amino-3-methylphenyl)methyl]-7-(furan-2-yl)triazolo[4,5-d]pyrimidin-5-amine Chemical compound C1=C(N)C(C)=CC(CN2C3=NC(N)=NC(=C3N=N2)C=2OC=CC=2)=C1 HQSBCDPYXDGTCL-UHFFFAOYSA-N 0.000 description 2
- NCWQLHHDGDXIJN-UHFFFAOYSA-N 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine Chemical compound ClC1=NC(C)=CC(C=2C(=NC(N)=NN=2)C=2C=CC(F)=CC=2)=C1 NCWQLHHDGDXIJN-UHFFFAOYSA-N 0.000 description 2
- 101000840545 Bacillus thuringiensis L-isoleucine-4-hydroxylase Proteins 0.000 description 2
- 229940123494 CD20 antagonist Drugs 0.000 description 2
- 229940122004 CD47 antagonist Drugs 0.000 description 2
- 229940123828 CD80 antagonist Drugs 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical group CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
- 208000012266 Needlestick injury Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 2
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 2
- 229940123387 PVRIG antagonist Drugs 0.000 description 2
- 229940122113 STING antagonist Drugs 0.000 description 2
- 101001037255 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Indoleamine 2,3-dioxygenase Proteins 0.000 description 2
- 229940123803 TIM3 antagonist Drugs 0.000 description 2
- XNBRWUQWSKXMPW-UHFFFAOYSA-N Tozadenant Chemical compound C1=2SC(NC(=O)N3CCC(C)(O)CC3)=NC=2C(OC)=CC=C1N1CCOCC1 XNBRWUQWSKXMPW-UHFFFAOYSA-N 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 229960003697 abatacept Drugs 0.000 description 2
- 229960004308 acetylcysteine Drugs 0.000 description 2
- 229950002916 avelumab Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000002619 cytotoxin Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 229950009791 durvalumab Drugs 0.000 description 2
- 229950006370 epacadostat Drugs 0.000 description 2
- -1 for example Substances 0.000 description 2
- 239000003517 fume Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- KRTIYQIPSAGSBP-KLAILNCOSA-N linrodostat Chemical compound C1(CCC(CC1)C1=C2C=C(F)C=CC2=NC=C1)[C@@H](C)C(=O)NC1=CC=C(Cl)C=C1 KRTIYQIPSAGSBP-KLAILNCOSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- CYYQMAWUIRPCNW-UHFFFAOYSA-N 2-butyl-9-methyl-8-(triazol-2-yl)purin-6-amine Chemical compound CN1C2=NC(CCCC)=NC(N)=C2N=C1N1N=CC=N1 CYYQMAWUIRPCNW-UHFFFAOYSA-N 0.000 description 1
- LAUZGQFZTMIABE-UHFFFAOYSA-N 3-(1h-pyrazol-4-yl)-1h-indole Chemical group C1=NNC=C1C1=CNC2=CC=CC=C12 LAUZGQFZTMIABE-UHFFFAOYSA-N 0.000 description 1
- VTCSOKNICUBHAL-UHFFFAOYSA-N 3-pyridin-3-yl-1h-indole Chemical class C=1NC2=CC=CC=C2C=1C1=CC=CN=C1 VTCSOKNICUBHAL-UHFFFAOYSA-N 0.000 description 1
- PWTBZOIUWZOPFT-UHFFFAOYSA-N 4-[2-[[7-amino-2-(2-furanyl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]phenol Chemical compound N=1C2=NC(C=3OC=CC=3)=NN2C(N)=NC=1NCCC1=CC=C(O)C=C1 PWTBZOIUWZOPFT-UHFFFAOYSA-N 0.000 description 1
- KURQKNMKCGYWRJ-HNNXBMFYSA-N 7-(5-methylfuran-2-yl)-3-[[6-[[(3s)-oxolan-3-yl]oxymethyl]pyridin-2-yl]methyl]triazolo[4,5-d]pyrimidin-5-amine Chemical group O1C(C)=CC=C1C1=NC(N)=NC2=C1N=NN2CC1=CC=CC(CO[C@@H]2COCC2)=N1 KURQKNMKCGYWRJ-HNNXBMFYSA-N 0.000 description 1
- 229940125979 ALX148 Drugs 0.000 description 1
- 108700001691 ALX148 Proteins 0.000 description 1
- 102000007471 Adenosine A2A receptor Human genes 0.000 description 1
- 108010085277 Adenosine A2A receptor Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 229940125565 BMS-986016 Drugs 0.000 description 1
- 229940125557 BMS-986207 Drugs 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010072135 Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100024649 Cell adhesion molecule 1 Human genes 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 101710088235 Envelope glycoprotein C homolog Proteins 0.000 description 1
- 229940125570 FS118 Drugs 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 1
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 1
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 description 1
- 101001102797 Homo sapiens Transmembrane protein PVRIG Proteins 0.000 description 1
- 241000341655 Human papillomavirus type 16 Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 229940123965 Immunoglobulin inhibitor Drugs 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- AEULVFLPCJOBCE-UHFFFAOYSA-N LSM-3027 Chemical compound C1=CC(OC)=CC=C1CCCN1C(N=C(N)N2C3=NC(=N2)C=2OC=CC=2)=C3C=N1 AEULVFLPCJOBCE-UHFFFAOYSA-N 0.000 description 1
- UTLPKQYUXOEJIL-UHFFFAOYSA-N LSM-3822 Chemical compound N1=CC=2C3=NC(C=4OC=CC=4)=NN3C(N)=NC=2N1CCC1=CC=CC=C1 UTLPKQYUXOEJIL-UHFFFAOYSA-N 0.000 description 1
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 1
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 1
- 208000036647 Medication errors Diseases 0.000 description 1
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 1
- 101100264174 Mus musculus Xiap gene Proteins 0.000 description 1
- FBKMWOJEPMPVTQ-UHFFFAOYSA-N N'-(3-bromo-4-fluorophenyl)-N-hydroxy-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole-3-carboximidamide Chemical compound NS(=O)(=O)NCCNC1=NON=C1C(=NO)NC1=CC=C(F)C(Br)=C1 FBKMWOJEPMPVTQ-UHFFFAOYSA-N 0.000 description 1
- KCWZGJVSDFYRIX-YFKPBYRVSA-N N(gamma)-nitro-L-arginine methyl ester Chemical compound COC(=O)[C@@H](N)CCCN=C(N)N[N+]([O-])=O KCWZGJVSDFYRIX-YFKPBYRVSA-N 0.000 description 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
- 229940125566 REGN3767 Drugs 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 101710090983 T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 1
- 102100035268 T-cell surface protein tactile Human genes 0.000 description 1
- 229940125567 TSR-033 Drugs 0.000 description 1
- 229940126302 TTI-621 Drugs 0.000 description 1
- 102000011117 Transforming Growth Factor beta2 Human genes 0.000 description 1
- 101800000304 Transforming growth factor beta-2 Proteins 0.000 description 1
- 102100039630 Transmembrane protein PVRIG Human genes 0.000 description 1
- 102000057288 Tryptophan 2,3-dioxygenases Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 description 1
- 101710128901 Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 229960005347 belatacept Drugs 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229950002256 cergutuzumab amunaleukin Drugs 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 229950007409 dacetuzumab Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940056913 eftilagimod alfa Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229950004647 emactuzumab Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 229950004003 fresolimumab Drugs 0.000 description 1
- 229950001109 galiximab Drugs 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 229940121569 ieramilimab Drugs 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 description 1
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 description 1
- 229950009034 indoximod Drugs 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- IQVRBWUUXZMOPW-PKNBQFBNSA-N istradefylline Chemical compound CN1C=2C(=O)N(CC)C(=O)N(CC)C=2N=C1\C=C\C1=CC=C(OC)C(OC)=C1 IQVRBWUUXZMOPW-PKNBQFBNSA-N 0.000 description 1
- 229950011263 lirilumab Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 229950007250 navoximod Drugs 0.000 description 1
- 229940017335 nulojix Drugs 0.000 description 1
- 229960003347 obinutuzumab Drugs 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229940035567 orencia Drugs 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229950010773 pidilizumab Drugs 0.000 description 1
- 229940126621 pogalizumab Drugs 0.000 description 1
- DTYWJKSSUANMHD-UHFFFAOYSA-N preladenant Chemical compound C1=CC(OCCOC)=CC=C1N1CCN(CCN2C3=C(C4=NC(=NN4C(N)=N3)C=3OC=CC=3)C=N2)CC1 DTYWJKSSUANMHD-UHFFFAOYSA-N 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229940121484 relatlimab Drugs 0.000 description 1
- JZAMQDDHRXHDFR-UHFFFAOYSA-N sch-412348 Chemical compound N1=CC=2C3=NC(C=4OC=CC=4)=NN3C(N)=NC=2N1CCN(CC1)CCN1C1=CC=C(F)C=C1F JZAMQDDHRXHDFR-UHFFFAOYSA-N 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229950007213 spartalizumab Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical class O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- ATFXVNUWQOXRRU-UHFFFAOYSA-N taminadenant Chemical compound BrC=1C(N)=NC(N2N=CC=C2)=NC=1N1C=CC=N1 ATFXVNUWQOXRRU-UHFFFAOYSA-N 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940126625 tavolimab Drugs 0.000 description 1
- 229940066453 tecentriq Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960003989 tocilizumab Drugs 0.000 description 1
- 239000008181 tonicity modifier Substances 0.000 description 1
- 229950000564 tozadenant Drugs 0.000 description 1
- 229940072041 transforming growth factor beta 2 Drugs 0.000 description 1
- 229950007217 tremelimumab Drugs 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229950005972 urelumab Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 229950003008 vipadenant Drugs 0.000 description 1
- 229940121351 vopratelimab Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
- A61J1/06—Ampoules or carpules
- A61J1/065—Rigid ampoules, e.g. glass ampoules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/1475—Inlet or outlet ports
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/16—Holders for containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
- A61J1/2003—Accessories used in combination with means for transfer or mixing of fluids, e.g. for activating fluid flow, separating fluids, filtering fluid or venting
- A61J1/2006—Piercing means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
- A61J1/2003—Accessories used in combination with means for transfer or mixing of fluids, e.g. for activating fluid flow, separating fluids, filtering fluid or venting
- A61J1/2006—Piercing means
- A61J1/201—Piercing means having one piercing end
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
- A61J1/2003—Accessories used in combination with means for transfer or mixing of fluids, e.g. for activating fluid flow, separating fluids, filtering fluid or venting
- A61J1/2048—Connecting means
- A61J1/2058—Connecting means having multiple connecting ports
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
- A61J1/2003—Accessories used in combination with means for transfer or mixing of fluids, e.g. for activating fluid flow, separating fluids, filtering fluid or venting
- A61J1/2068—Venting means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
- A61J1/2003—Accessories used in combination with means for transfer or mixing of fluids, e.g. for activating fluid flow, separating fluids, filtering fluid or venting
- A61J1/2068—Venting means
- A61J1/2075—Venting means for external venting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
- A61J1/2089—Containers or vials which are to be joined to each other in order to mix their contents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/002—Compounding apparatus specially for enteral or parenteral nutritive solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/1407—Infusion of two or more substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/1407—Infusion of two or more substances
- A61M5/1409—Infusion of two or more substances in series, e.g. first substance passing through container holding second substance, e.g. reconstitution systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/1413—Modular systems comprising interconnecting elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M5/14248—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M2005/14268—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body with a reusable and a disposable component
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2209/00—Ancillary equipment
- A61M2209/04—Tools for specific apparatus
- A61M2209/045—Tools for specific apparatus for filling, e.g. for filling reservoirs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/1407—Infusion of two or more substances
- A61M5/1408—Infusion of two or more substances in parallel, e.g. manifolds, sequencing valves
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Fluid Mechanics (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Engineering & Computer Science (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medical Treatment And Welfare Office Work (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medicinal Preparation (AREA)
Description
Claims (11)
- 所定の選択された複数の薬剤成分を送達するための配合剤送達装置であって、
前記複数の薬剤成分の各々は薬剤バイアルに収容され、
前記装置は、複数のモジュールと、ベーストレイとを備え、
前記複数のモジュールの各々は、
薬剤バイアルを収容するように形成される内部空間を包括的に定義する本体及び蓋と、
移動可能に前記内部空間に配置されるスパイクプレートであって、前記スパイクプレートは自由端で終了する突出するカニューレ及び第1及び第2ポートを有し、第1及び第2開口は前記自由端に形成され、第1及び第2ルーメンはそれぞれ前記自由端から延びて前記カニューレを通って前記第1及び第2ポートで終了する、スパイクプレートと、
を有し、
前記ベーストレイは、
各々、前記複数のモジュールの一つを挿入式で受けるように形成される複数の穴を規定する骨格と、
前記複数の穴の各々において、対応する穴で受けたモジュールの前記第1及び第2ポートに通じるように形成される第1及び第2注入口と、
特定の穴の前記第2注入口を前記特定の穴に隣接する穴の前記第1注入口に接続して、流体がこれらの間で流れるようにする通路と、
を有し、
前記複数の穴のそれぞれにおいて、前記第1及び第2注入口は、対応するモジュールの前記スパイクプレートを、前記モジュールが穴に挿入された状態で、静止位置に維持するように構成される、
配合剤送達装置。 - 前記複数のモジュールから前記複数の薬剤成分を引き出すための負圧源を更に備える、
請求項1に記載の配合剤送達装置。 - 前記ベーストレイは、ハウジングを備え、
前記負圧源は、前記ハウジング内に配置される、
請求項2に記載の配合剤送達装置。 - 前記スパイクプレートは、全てが前記内部空間に配置される、
請求項1に記載の配合剤送達装置。 - 前記蓋は、開口を有する、
請求項1~4のいずれか一つに記載の配合剤送達装置。 - 前記スパイクプレートは、前記開口の近くの初期状態から前記開口から離れた前記内部空間内に前記蓋に対して移動可能である、
請求項5に記載の配合剤送達装置。 - 前記複数の穴の各々において、対応するモジュールが穴に挿入されると、前記第1及び第2注入口が前記開口を通して前記スパイクプレートの前記第1及び第2ポートに結合して、それらの間に封止された流体流路を形成する、
請求項5又は6に記載の配合剤送達装置。 - 対応するモジュールの前記スパイクプレートが前記静止位置にあり、前記モジュールが前記穴に挿入されると、対応するモジュールにおいて、前記蓋が、前記スパイクプレートに対して移動して、前記スパイクプレートを前記蓋の前記開口から離れるように移動させる、
請求項5~7のいずれか一つに記載の配合剤送達装置。 - 前記スパイクプレートは、初期状態において、解放可能に保持される、
請求項1~8のいずれか一つに記載の配合剤送達装置。 - 前記複数のモジュールの少なくとも一つは、前記内部空間に収容される薬剤バイアルを更に備え、
前記薬剤バイアルは、隔壁を有し、
対応するモジュールを穴に十分に挿入すると、前記スパイクプレートの前記カニューレが前記薬剤バイアルの前記隔壁を完全に貫通する、
請求項1~9のいずれか一つに記載の配合剤送達装置。 - 前記蓋は、ヒンジ構造で前記本体に取り付けられる、
請求項1~10のいずれか一つに記載の配合剤送達装置。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023053052A JP7434636B2 (ja) | 2018-05-11 | 2023-03-29 | 配合剤送達装置 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862670266P | 2018-05-11 | 2018-05-11 | |
US62/670,266 | 2018-05-11 | ||
PCT/US2019/031791 WO2019217864A1 (en) | 2018-05-11 | 2019-05-10 | Combinatorial drug delivery device |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023053052A Division JP7434636B2 (ja) | 2018-05-11 | 2023-03-29 | 配合剤送達装置 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021522927A JP2021522927A (ja) | 2021-09-02 |
JP7254835B2 true JP7254835B2 (ja) | 2023-04-10 |
Family
ID=66655467
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020563421A Active JP7254835B2 (ja) | 2018-05-11 | 2019-05-10 | 配合剤送達装置 |
JP2020563437A Pending JP2021522929A (ja) | 2018-05-11 | 2019-05-10 | 配合剤送達装置用の直列接続可能な薬剤モジュール |
JP2020563440A Pending JP2021523774A (ja) | 2018-05-11 | 2019-05-10 | 併用療法の送達のための装置及びシステム |
JP2023053052A Active JP7434636B2 (ja) | 2018-05-11 | 2023-03-29 | 配合剤送達装置 |
JP2023079258A Pending JP2023099218A (ja) | 2018-05-11 | 2023-05-12 | 併用療法の送達のための装置及びシステム |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020563437A Pending JP2021522929A (ja) | 2018-05-11 | 2019-05-10 | 配合剤送達装置用の直列接続可能な薬剤モジュール |
JP2020563440A Pending JP2021523774A (ja) | 2018-05-11 | 2019-05-10 | 併用療法の送達のための装置及びシステム |
JP2023053052A Active JP7434636B2 (ja) | 2018-05-11 | 2023-03-29 | 配合剤送達装置 |
JP2023079258A Pending JP2023099218A (ja) | 2018-05-11 | 2023-05-12 | 併用療法の送達のための装置及びシステム |
Country Status (7)
Country | Link |
---|---|
US (5) | US11497685B2 (ja) |
EP (6) | EP4344695A3 (ja) |
JP (5) | JP7254835B2 (ja) |
KR (3) | KR20210006911A (ja) |
CN (3) | CN112135597A (ja) |
ES (1) | ES2968900T3 (ja) |
WO (3) | WO2019217820A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7254835B2 (ja) * | 2018-05-11 | 2023-04-10 | ブリストル-マイヤーズ スクイブ カンパニー | 配合剤送達装置 |
KR20220097946A (ko) * | 2019-11-08 | 2022-07-08 | 브리스톨-마이어스 스큅 컴퍼니 | 직렬 연결 가능 약물 모듈을 위한 교번적 유체 경로 |
EP4054674A4 (en) | 2019-11-08 | 2022-12-21 | Bristol-Myers Squibb Company | SYSTEM FOR CHECKING THE ACCURACY OF SERIALLY CONNECTED DRUG MODULES IN A COMBINATORY DRUG RELEASE DEVICE |
KR102561236B1 (ko) * | 2021-02-09 | 2023-07-28 | 윤지영 | 바이알 홀더 및 이를 포함하는 바이알 홀더 패키지 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020007671A1 (en) | 1998-11-13 | 2002-01-24 | Gilad Lavi | Device for measuring a volume of drug |
US20110108158A1 (en) | 2009-11-06 | 2011-05-12 | Roche Diagnostics International Ltd. | Device, Kit, And Method For Filling a Flexible Reservoir Container In A Negative Pressure Chamber |
WO2013157203A1 (ja) | 2012-04-18 | 2013-10-24 | パナソニック株式会社 | 薬剤移注装置及び薬剤移注方法 |
JP2014503280A (ja) | 2010-12-24 | 2014-02-13 | エブオン | 2成分を混合するための装置 |
US20150257974A1 (en) | 2014-03-14 | 2015-09-17 | Deka Products Limited Partnership | Compounder Apparatus |
WO2016205687A1 (en) | 2015-06-19 | 2016-12-22 | Baxalta Incorporated | Pooling device for single or multiple containers |
WO2017140850A1 (de) | 2016-02-19 | 2017-08-24 | Fresenius Kabi Deutschland Gmbh | Anlage zur herstellung einer medizinischen zubereitung |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4085782A (en) * | 1976-05-24 | 1978-04-25 | Carlson Harold W | Vaccine and medicament dispensing system |
US5037390A (en) * | 1989-12-28 | 1991-08-06 | Kenneth Raines | System and method for mixing parenteral nutrition solutions |
US5122116A (en) * | 1990-04-24 | 1992-06-16 | Science Incorporated | Closed drug delivery system |
US5304165A (en) * | 1991-12-09 | 1994-04-19 | Habley Medical Technology Corporation | Syringe-filling medication dispenser |
US5329976A (en) * | 1991-12-09 | 1994-07-19 | Habley Medical Technology Corporation | Syringe-filling and medication mixing dispenser |
US5569181A (en) * | 1993-10-28 | 1996-10-29 | Medrad, Inc. | Sterility assurance for contrast delivery system |
US6719719B2 (en) | 1998-11-13 | 2004-04-13 | Elan Pharma International Limited | Spike for liquid transfer device, liquid transfer device including spike, and method of transferring liquids using the same |
US6699230B2 (en) * | 2000-05-10 | 2004-03-02 | Minnesota Medical Physics, Llc | Apparatus and method for out-of-hospital thrombolytic therapy |
US7150735B2 (en) * | 2002-05-16 | 2006-12-19 | Scott Laboratories, Inc. | Drug container entry mechanisms and method |
DE10308401A1 (de) * | 2003-02-27 | 2004-09-23 | Dräger Medical AG & Co. KGaA | Vorrichtung zur Dosierung von medizinischen Wirkstoffen |
DE102004010062B3 (de) * | 2004-03-02 | 2005-09-08 | Drägerwerk AG | Vorrichtung zur Dosierung von Substanzen |
US7963945B2 (en) * | 2005-12-14 | 2011-06-21 | Hewlett-Packard Development Company, L.P. | Replaceable supplies for IV fluid delivery systems |
US20070299400A1 (en) * | 2006-03-16 | 2007-12-27 | Seattle Medical Technologies | Infusion device with dome pump |
WO2007107406A2 (en) * | 2006-03-17 | 2007-09-27 | Novo Nordisk A/S | A connectable device and a device assembly for delivering a liquid drug |
ITMO20060097A1 (it) * | 2006-03-24 | 2007-09-25 | Giuseppe Zucca | Dispositivo e metodo per la diluizione e l'allestimento di farmaci antiblastici |
US20080164273A1 (en) * | 2007-01-09 | 2008-07-10 | Brent Dallman | Drug storage, indexing and dispensing system |
ES2785056T3 (es) * | 2007-07-02 | 2020-10-05 | Hoffmann La Roche | Un dispositivo para la administración de fármacos |
CH700740A2 (de) * | 2009-04-01 | 2010-10-15 | Ludger Dr Fischer | Verfahren und Einrichtung zum automatisierten sterilen Dosieren und Mischen von Infusionen. |
WO2010141632A2 (en) * | 2009-06-02 | 2010-12-09 | Yukon Medical, Llc | Multi-container transfer and delivery device |
IN2012DN01817A (ja) * | 2009-07-01 | 2015-06-05 | Fresenius Med Care Hldg Inc | |
EP2305204A1 (en) * | 2009-09-30 | 2011-04-06 | Fresenius Medical Care Deutschland GmbH | Tubing set having an insert for the infusion of drugs |
IL201323A0 (en) * | 2009-10-01 | 2010-05-31 | Medimop Medical Projects Ltd | Fluid transfer device for assembling a vial with pre-attached female connector |
EP2335755A1 (en) | 2009-12-17 | 2011-06-22 | Sanofi-Aventis Deutschland GmbH | Device and method for delivery of two or more drug agents |
WO2011131775A1 (en) | 2010-04-23 | 2011-10-27 | Sanofi-Aventis Deutschland Gmbh | Coded cartridge holder system for a fluid delivery device |
DK2646070T3 (en) | 2010-11-29 | 2015-05-04 | Sanofi Aventis Deutschland | PUMP PLASTER WITH MULTIPLE RESERVES |
EP2462913A1 (en) * | 2010-12-10 | 2012-06-13 | Fresenius Medical Care Deutschland GmbH | Insert and vial for the infusion of liquids |
US9433556B2 (en) | 2010-12-30 | 2016-09-06 | Ge Healthcare Limited | Multi-vial dispensing |
US20130253430A1 (en) * | 2011-01-18 | 2013-09-26 | Sanofi-Aventis Deutschland Gmbh | Multi-Reservoir Pump Patch |
EP2672946A2 (en) * | 2011-02-13 | 2013-12-18 | The Regents of The University of California | Fluid delivery system |
US9211231B2 (en) * | 2013-03-14 | 2015-12-15 | Carefusion 303, Inc. | Vial adapter for side engagement of vial cap |
US20150258275A1 (en) * | 2013-03-15 | 2015-09-17 | Susan J. MACK | Intravenous medication delivery system |
EP4144390A3 (en) | 2013-06-18 | 2023-07-12 | Enable Injections, Inc. | Vial transfer and injection apparatus and method |
DE102014104281B3 (de) * | 2014-03-27 | 2015-09-10 | Medac Gesellschaft für klinische Spezialpräparate mbH | Transfervorrichtung |
EP3834863A1 (en) | 2015-03-02 | 2021-06-16 | Amgen, Inc | Device and method for making aseptic connections |
CN106345051A (zh) * | 2016-11-25 | 2017-01-25 | 崔丽林 | 微型注射针及其集成装置 |
JP7254835B2 (ja) * | 2018-05-11 | 2023-04-10 | ブリストル-マイヤーズ スクイブ カンパニー | 配合剤送達装置 |
-
2019
- 2019-05-10 JP JP2020563421A patent/JP7254835B2/ja active Active
- 2019-05-10 KR KR1020207032410A patent/KR20210006911A/ko not_active Application Discontinuation
- 2019-05-10 KR KR1020207032412A patent/KR20210008344A/ko not_active Application Discontinuation
- 2019-05-10 EP EP24157510.9A patent/EP4344695A3/en active Pending
- 2019-05-10 JP JP2020563437A patent/JP2021522929A/ja active Pending
- 2019-05-10 US US17/047,449 patent/US11497685B2/en active Active
- 2019-05-10 CN CN201980031352.4A patent/CN112135597A/zh active Pending
- 2019-05-10 US US17/047,262 patent/US20210154097A1/en active Pending
- 2019-05-10 EP EP24152460.2A patent/EP4331556A3/en active Pending
- 2019-05-10 WO PCT/US2019/031727 patent/WO2019217820A1/en active Application Filing
- 2019-05-10 JP JP2020563440A patent/JP2021523774A/ja active Pending
- 2019-05-10 EP EP23202850.6A patent/EP4282393A3/en active Pending
- 2019-05-10 US US17/047,126 patent/US11944588B2/en active Active
- 2019-05-10 WO PCT/US2019/031791 patent/WO2019217864A1/en active Application Filing
- 2019-05-10 ES ES19728182T patent/ES2968900T3/es active Active
- 2019-05-10 WO PCT/US2019/031762 patent/WO2019217845A1/en active Application Filing
- 2019-05-10 CN CN201980031354.3A patent/CN112118821A/zh active Pending
- 2019-05-10 EP EP19726832.9A patent/EP3790524B1/en active Active
- 2019-05-10 EP EP19728182.7A patent/EP3790526B1/en active Active
- 2019-05-10 KR KR1020207032409A patent/KR20210008839A/ko not_active Application Discontinuation
- 2019-05-10 CN CN201980031874.4A patent/CN112105329A/zh active Pending
- 2019-05-10 EP EP19726835.2A patent/EP3790525B1/en active Active
-
2022
- 2022-10-26 US US17/973,877 patent/US11801199B2/en active Active
-
2023
- 2023-03-29 JP JP2023053052A patent/JP7434636B2/ja active Active
- 2023-05-12 JP JP2023079258A patent/JP2023099218A/ja active Pending
- 2023-09-23 US US18/473,233 patent/US20240009081A1/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020007671A1 (en) | 1998-11-13 | 2002-01-24 | Gilad Lavi | Device for measuring a volume of drug |
US20110108158A1 (en) | 2009-11-06 | 2011-05-12 | Roche Diagnostics International Ltd. | Device, Kit, And Method For Filling a Flexible Reservoir Container In A Negative Pressure Chamber |
JP2014503280A (ja) | 2010-12-24 | 2014-02-13 | エブオン | 2成分を混合するための装置 |
WO2013157203A1 (ja) | 2012-04-18 | 2013-10-24 | パナソニック株式会社 | 薬剤移注装置及び薬剤移注方法 |
US20150257974A1 (en) | 2014-03-14 | 2015-09-17 | Deka Products Limited Partnership | Compounder Apparatus |
WO2016205687A1 (en) | 2015-06-19 | 2016-12-22 | Baxalta Incorporated | Pooling device for single or multiple containers |
WO2017140850A1 (de) | 2016-02-19 | 2017-08-24 | Fresenius Kabi Deutschland Gmbh | Anlage zur herstellung einer medizinischen zubereitung |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7254835B2 (ja) | 配合剤送達装置 | |
Champiat et al. | Intratumoral immunotherapy: from trial design to clinical practice | |
KR20240014039A (ko) | 급속 주입을 통해 모노클로날 및/또는 폴리클로날 항체치료를 투여하기 위한 방법, 시스템, 및 장치 | |
US20220395631A1 (en) | Radially adjustable multi-cartridge combinatorial drug delivery device for subcutaneous injection | |
JP2023501400A (ja) | 組み合わせ薬物送達デバイスの、直列接続された複数の薬物モジュールの正確さを確認するためのシステム | |
WO2024123586A1 (en) | Radially adjustable multi-cartridge combinatorial drug delivery device for subcutaneous injection with cross element | |
WO2024110558A1 (en) | Adapter for filling and subsequent closing of a pharmaceutical composition container, and container with adapter | |
WO2021081161A1 (en) | Systems and components for drug delivery and components for preparation of the same | |
JP2023501389A (ja) | 組み合わせ薬剤送達装置の直列接続可能な薬剤モジュール用のピストンバルブ | |
WO2023237357A1 (en) | Drug delivery control arrangement, and injector | |
CN114727908A (zh) | 探询组合药物递送装置中的串联连接的药物模块的系统 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210113 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220406 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221115 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230214 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230228 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230329 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7254835 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |